ASSOCIATION OF INCREASED ONCOSTATIN M WITH ADVERSE LEFT VENTRICULAR REMODELING IN PATIENTS WITH MYOCARDIAL INFARCTION

POVEZANOST POVEĆANOG ONKOSTATINA M SA NEŽELJENIM LEVIM VERTIKULARNIM REMODELIRANJEM, KOD PACIJENATA SA INFARKTOM MIOKARDA

Anna M. Gusakova, Tatiana E. Suslova, Maria A. Kercheva, Irina V. Kologrivova, Tamara R. Ryabova, Vyacheslav V. Ryabov

Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Science, Tomsk, Russian Federation

Summary

Background: The study of laboratory biomarkers that reflect the development of adverse cardiovascular events in the postinfarction period is of current relevance. The aim of the present study was evaluation of oncostatin M (OSM) concentration changes in the early and late stages of myocardial infarction and evaluation of the possibility of its use in prediction of adverse left ventricular (LV) remodeling in patients with myocardial infarction with ST-elevated segment (STEMI).

Methods: The study involved 31 patients with STEMI admitted in the first 24 hours after the onset of MI and 30 patients with chronic coronary artery disease as a control group. Echocardiographic study was performed on day 3 and in 6 months after STEMI. The serum levels of biomarkers were evaluated on the day of hospital admission and 6 months after MI using multiplex immunoassay.

Results: OSM level increased during the first 24 h after the onset of the disease, with the following decrease in 6 months. OSM concentration at admission had correlated with echocardiography parameters and Nt-proBNP, troponin I, CK-MB levels. Our study has demonstrated association of the increased levels of OSM at the early stages of STEMI with development of the adverse LV remodeling in 6 months after the event.

Conclusions: Elevation of OSM levels in the first 24 h after STEMI is associated with the development of the adverse LV remodeling in the long-term post-infarction period.

Keywords: pro-inflammatory cytokines, oncostatin M, myocardial infarction, adverse left ventricular remodeling

List of abbreviations: CAD, coronary artery disease; CK-MB, creatine phosphokinase cardiac specific isoenzyme MB; ESV, end systolic volumes; LV, left ventricular; Nt-proBNP, N-terminal fragment of brain natriuretic peptide; OSM, oncostatin M; STEMI, myocardial infarction with ST-elevated segment.
Introduction

Myocardial infarction (MI) remains the leading cause of mortality and morbidity all over the world. Patients who suffered MI with ST-elevated segment (STEMI) have an increased risk of sudden death and recurrent events in the future, mainly due to the subsequently developing heart failure (HF) both with the preserved and reduced ejection fraction (1, 2).

Even though modern therapeutic approaches allowed to significantly improve management of STEMI patients, the post-infarction HF still represents a challenge in the modern medicine (3). Decompensation of the congestive HF represents one of the major causes of mortality in STEMI patients (4) and leads to the re-admission to the hospital in 20% of cases (5–6). The prior myocardial infarction is known to initiate the processes of structural rearrangement of myocardium, leading to the development of post-infarct remodeling. The underlying pathophysiological basis for adverse myocardial remodeling is infarct expansion. The degree of infarct expansion depends upon the size of infarction, wall stress in the left ventricle and improper myocardial healing (7). Myocardial healing is the least manageable process in this triad, known to be dependent upon regulation of inflammation and its resolution.

Neutrophils and monocytes/macrophages are recruited to the injured myocardium, performing phagocytosis of the necrotic tissue meanwhile releasing mediators of inflammation, such as leukotrienes, thromboxane, prostacyclin, which may increase tissue damage even further (8). Myocardial necrosis leads to activation of the compliment system, production of the reactive oxygen species and initiates cytokine cascade and acute phase proteins’ production by endothelial cells, monocytes and macrophages. The size of injury determines the power of inflammatory response, while impairments in the synthesis of inflammatory mediators may affect the success of the myocardial healing and patients’ prognosis. Cytokines synthesized in the focus of inflammation, influence all the cells, responsible for the proper myocardial remodeling, including cells of the innate and adaptive immunity, fibroblasts and endotheliocytes (9). With all the variety of the known cytokines involved in post-infarct myocardial inflammation and healing, biomarkers, allowing to predict whether the process of resolution of inflammation and myocardial remodeling in a definite patient will be successful, are absent.

Cytokines of IL-6 family are known to play an important role in initiation, sustainment and resolution of the local and systemic inflammation (10, 11). Pleiotropic cytokine oncostatin M (OSM) is secreted by T cells, monocytes/macrophages, dendritic cells and neutrophils and is known to be tightly involved in the pathogenesis of cardiovascular disorders (12–17). Among the biological functions of OSM are regulation of proliferation, inflammation, cellular differenti-
the American and European Associations of Echocardiography. End diastolic and systolic volumes (ESV), and left ventricular ejection fraction (LV EF) were determined using Simpson’s method. To assess post infarction myocardial remodeling, the dynamics of ESV was evaluated on day 3 of hospital admission and in 6 months after MI. The widely accepted approach to acknowledge the presence of the adverse left ventricular remodeling is an observed increase of left ventricular end-diastolic (and/or end-systolic) ventricular volume (LVEDV and/or LVESV) by at least 20% since the first post-myocardial measurement (24). Hence the patients were divided into groups based on the results of echocardiography: group 1 – patients with no LV remodeling (ΔESV <20%); group 2 – patients with adverse LV remodeling (ΔESV 20%).

Serum biomarkers

Venous blood was drawn into sterile vacutainers at admission to the clinics and in 6 months after STEMI. Obtained blood samples have been stored at the room temperature for 30 min and were centrifuged at 3000 rpm for 15 min. The serum samples have been collected and stored at −40 °C until the measurements were performed.

The levels of OSM, troponin I, N-terminal fragment of brain natriuretic peptide (Nt-proBNP) and creatine phosphokinase cardiac specific isoenzyme MB (CK-MB) were evaluated in serum using multiplex immunoassay with the FLEXMAP 3D System (Lumine Corporation, USA) and the Human Cardiovascular Disease Panel 1 (Merck KGaA, Darmstadt, Germany). The study was conducted using the Core Facility »Medical genomics«, Tomsk NRMC.

Statistical analysis

The analysis of the obtained data was performed using the STATISTICA 10.0 and SPSS 10.0 software. The type of the distribution of the data was evaluated by Kolmogorov-Smirnov test. Results were presented as mean ± standard deviation (x ± SD) in the case of normal distribution and as the median value and the interquartile range (Me (Q1; Q3)) in the case of non-normal distribution. Wilcoxon test was used to estimate the significance of differences in the values of the dependent parameters. The Mann-Whitney U-test was used to estimate the significance of differences between independent groups. The Spearman’s rank correlation coefficient was calculated to assess the relationship between the parameters. A value of p<0.05 was considered statistically significant in all statistical evaluations. Linear regression model was created to evaluate input of OSM in the development of the left ventricle adverse remodeling. The prognostic value was determined using the ROC analysis. The area below the ROC curve was calculated, and the sensitivity and specificity were calculated to evaluate the characteristic curves.

Results

Clinical characteristics of STEMI and chronic CAD patients were comparable (Table I).

The serum levels of all studied biomarkers in STEMI patients at admission were increased compared to patients with chronic CAD (Table II).

Only OSM remained elevated in STEMI patients in 6 months of observation compared to chronic CAD patients (Table II).

We have revealed the significant decrease of the OSM concentration in the long-term post-infarct period (6 months of observation) compared to the elevat-

| Table I Clinical and anamnestic characteristics of patients with acute STEMI and chronic CAD. |
| Parameter | STEMI patients (n = 31) | Chronic CAD patients (n = 30) | p     |
| Age, years | 59.3 ± 8.4 | 60.4 ± 7.1 | 0.606 |
| Male, gender, n (%) | 23 (74) | 19 (63) | 0.289 |
| Obesity, n (%) | 21 (68) | 25 (83) | 0.359 |
| Hypertension, n (%) | 24 (77) | 27 (90) | 0.748 |
| Diabetes mellitus, n (%) | 8 (26) | 9 (30) | 0.531 |
| Dyslipidemia, n (%) | 22 (71) | 18 (60) | 0.812 |

Abbreviations: STEMI, myocardial infarction with ST-elevated segment; CAD, coronary artery disease; p, the level of statistical significance of differences between the STEMI patients and CAD patients.
Table II Serum concentration of biomarkers in patients with STEMI and chronic CAD.

| Biomarker     | Patients with STEMI (n = 31) | Patients with chronic CAD (n = 30) | p T1-T2 | p* | p** |
|---------------|------------------------------|-----------------------------------|---------|----|-----|
|               | Hospital admission (T1)      | 6 month after STEMI (T2)          |         |    |     |
| OSM, ng/L     | 46.90 [18.91; 75.73]         | 13.12 [6.88; 19.58]               | 4.35    | 1.48; 12.63 | < 0.001 | < 0.001 | 0.006 |
| Troponin, μg/L| 147.48 [18.65; 431.18]       | 0.06 [0.03; 0.21]                | 0.19    | 0.07; 0.33 | < 0.001 | < 0.001 | 0.137 |
| Nt-proBNP, ng/L| 1127 [467.02; 1611]          | 325.64 [235.65; 554.53]          | 381.19  | 220.91; 536.12 | 0.022 | 0.002 | 0.583 |
| CK-MB, μg/L   | 213.63 [125.16; 259.69]      | 2.85 [1.88; 3.13]                | 3.39    | 2.07; 5.22 | < 0.001 | < 0.001 | 0.101 |

Abbreviations: p T1-T2 – the level of statistical significance of differences between STEMI patients at admission and in 6 months; p* – the level of statistical significance of differences between the STEMI patients at admission and CAD patients; p** – the level of statistical significance of differences between the patients in 6 months after STEMI and CAD patients.

Figure 1 Correlations between oncostatin M and markers of myocardial injury, myocardial stress and necrosis in patients with acute primary STEMI at the first 24 hours from the onset of the disease.
A – Troponin I, B – N-terminal fragment of brain natriuretic peptide Nt-proBNP, C – creatine phosphokinase cardiac specific isoenzyme MB, CK-MB.

Figure 2 Correlations between oncostatin M at the first 24 hours from the onset of the disease and echocardiography parameters in STEMI patients.
A – left ventricular ejection fraction (LV EF) value 6 months after MI, B – the increased end systolic volumes (Δ ESV).
Figure 3 The biomarkers dynamics in patients with STEMI.
A – oncostatin M, B – Nt-proBNP; C – troponin I, D – CK–MB; Comments: 1, group 1 (ΔESV less than 20%); 2, group 2 (ΔESV more than 20%); scale a, for biomarkers values obtained in 1st day, scale b, for biomarkers values obtained in 6 month after MI.

Table III Medical history and clinical characteristics of patients with acute STEMI depending to the development of left ventricular adverse remodeling.

| Parameter                                                                 | Group 1 (n = 17)       | Group 2 (n = 14)       | p   |
|---------------------------------------------------------------------------|------------------------|------------------------|-----|
| Killip class at the admission, 1 / 2 / 3 / 4, n                           | 12 / 3 / 1/ 1          | 10 / 3 / 1 / -         | 0.810 |
| Preinfarction angina, n                                                  | 8                      | 8                      | 0.164 |
| Reperfusion time (hours)                                                 | 5.2 ± 2.2              | 4.8 ± 2.8              | 0.236 |
| Complete revascularization, n (%)                                        | 11 (64)                | 8 (57)                 | 0.241 |
| 1/2/3 vascular lesion coronary arteries, n                               | 15 / 0 / 1             | 9 / 5 / 0              | 0.134 |
| Thrombolysis + percutaneous coronary intervention, n (%)                 | 10 (59)                | 7 (50)                 | 0.257 |
| Time from pain onset-PCI center (hours)                                  | 4.2 ± 2.5              | 4.1 ± 3.2              | 0.217 |
| LV EDV (3d day), mL                                                      | 115.0 ± 19.7           | 89.6 ± 21.2            | 0.151 |
| EDV (day 3, 6 month, %)                                                  | -2.5 [-14.3; 9.8]      | -21.3 [-34.5; -5.7]    | 0.000 |
| LV ESV (3d day), mL                                                      | 53.6 ± 12.5            | 37.7 ± 10.4            | 0.016 |
| ESV (day 3, 6 month, %)                                                  | -3.1 [-17.3; 8.3]      | -33.9 [-51.9; -25.4]   | 0.000 |
| LV EF (3d day), %                                                        | 53.0 ± 8.7             | 57.1 ± 10.4            | 0.104 |
| LV EF (6 month), %                                                       | 55.1 ± 8.8             | 51.8 ± 8.3             | 0.012 |
| HF NYHA >1 at the discharge, n                                           | 0                      | 1                      | 0.873 |
| Angina pectoris FC III, n                                                | 1                      | 2                      | 0.351 |
| Recurrent MI, n                                                          | 0                      | 1                      | 0.599 |
| Dead, n                                                                  | 0                      | 0                      | -    |

Abbreviations: EDV, end diastolic volumes; ESV, end systolic volumes; LVEF, left ventricular ejection fraction; HF, heart failure; MI, myocardial infarction.
ed values at admission (Table II). Other biomarkers (troponin I, Nt-proBNP, CK-MB) were also considerably elevated at admission and significantly decreased in 6 months (Table II).

The results of correlation analysis demonstrated strong direct relations between OSM and widely acknowledged biomarkers of myocardial injury, stress and necrosis: troponin I, Nt-proBNP and CK-MB (Figure 1). We have also observed correlations between OSM and troponin I in 6 months of follow-up (R = 0.751, p = 0.0005).

During analysis of interactions between concentrations of biomarkers and long-term echocardiographic data we revealed negative correlations between OSM concentration at admission and EF LV in 6 months of observation after STEMI (Figure 2A). Concentration of OSM at admission was also negatively related to the values of increase of the LV end-systolic volume (ΔESV) (Figure 2B).

The total group of patients was divided into 2 groups: group 1 – patients without LV remodeling (ΔESV < 20%); group 2 – patients with adverse LV remodeling (ΔESV ≥ 20%). Medical history and clinical characteristics of patients depending on the presence of the adverse LV remodeling are represented in Table III.

The comparative analysis demonstrated that patients in group 2 had significantly elevated values of ΔEDV and ΔESV in 6 months, ESV LF at day 3 and LV EF in 6 months compared to patients in group 1 (Table III).

We have also revealed significant differences in the level of OSM at admission in groups 1 and 2 (Figure 3). Concentration of OSM decreased in both groups in 6 months, being comparable in groups 1 and 2 (Figure 3).

Even though Troponin I and CK-MB have been shown to reflect the infarct size and hence predict the development of adverse remodeling (24), we did not detect the statistically significant difference of these biomarkers concentrations in two groups. The level of NT-proBNP was also comparable in groups 1 and 2 (Figure 3), probably due to the wide spread of values.

We have created the model of the paired logistic regression with binary dependent variable to evaluate input of OSM in the development of the adverse LV remodeling. The dependent variable had taken the value «1» if a patient should have been assigned to the group 1, and value «2» if a patient should have been assigned to the group 2. The model employed OSM as a predictor. Logistic regression demonstrated that elevated concentration of OSM at admission was associated with adverse LV remodeling in 6 months (95% CI, 0.57–0.87; p < 0.05). The logistic regression model had the level of the statistical significance p = 0.002, the Chi-square = 13.965. The parameters of the logistic regression are represented in Table IV.

| Parameters          | Constant B | OSM  |
|---------------------|------------|------|
| Estimate            | -1.87      | 0.077|
| Standard Error      | 0.954      | 0.031|
| Wald’s Chi-square   | 3.822      | 6.185|
| p-value             | 0.051      | 0.013|
| Odds ratio          | 0.155      | 2.079|
| -95% CI             | 0.022      | 2.014|
| +95% CI             | 1.084      | 2.149|

Abbreviations: OSM, oncostatin M; CI, confidence interval.

The ROC analysis showed that the OSM measured at admission to the hospital is a promising informative indicator for predicting an increase in LVESV in 6 months after MI. The area below the ROC curve was 0.867 (p < 0.05), which made it possible to classify it as «of high quality» (Figure 4). The optimal sensitivity/specificity ratio was 83.3 and 60%, respectively. The OSM value exceeding 18.40 ng/L was associated with an increase in ESV in the long-term post infarction period by more than 20%.

Discussion

Our study has demonstrated association of the increased levels of OSM at the early stages of STEMI with development of the adverse LV remodeling in 6 months after the event. OSM concentration in patients with STEMI at admission had also correlated with the echocardiography parameters in 6 months.
OSM is known to have multiple biological functions, including regulation of hematopoiesis, proliferation, inflammation, differentiation of mesenchyme stem cells, apoptosis and various tissues' regeneration (15–14, 19). The possible underlying mechanisms leading to the revealed between-groups differences in expression of OSM depending on ΔESV values might be variability in infiltration of myocardium with macrophages, different kinetics of OSM release as well as different features of signal transduction through the specific receptors (25).

Increase of the circulating levels of OSM in subjects with coronary artery disease, heart failure, pulmonary arterial hypertension, atrial fibrillation has been demonstrated in a number of experimental and clinical studies (23, 26–28). It became obvious that the data obtained for the role of OSM in heart function depend on the type of the pathological condition and are often quite contradictory.

Thus, OSM secreted by macrophages in atherosclerotic plaques may favor progression of atherosclerosis and dysfunction of the vascular endothelium (13, 18). Besides influence on collagen production, proliferation and migration of smooth muscle cells, OSM may influence fibrosis, regulating balance between metalloproteinases and their inhibitors in connective tissue (14).

On the other hand a number of studies demonstrated a cardio protective role of OSM (29–30). This effect may be associated with employment of secondary messengers, associated with the specific intracellular enzymes and regulatory molecules.

The prior AMI is known to initiate processes of the structural reorganization in myocardium, leading to the development of post-infarct remodeling. Chronic subclinical inflammation, accompanied by the prolonged release of inflammatory cytokines, has a great impact on this process. The data on the involvement of OSM in heart remodeling in patients after AMI remain controversial and scarce.

In the recent work of Han et al. (31) the authors demonstrated that in experimental settings increased OSM favors myocardial healing via reduction of the cardiac fibrosis and preferable polarization of macrophages from M1 to M2 phenotype. However, the fact that these results have been obtained in mice with the follow-up period not exceeding 2 weeks complicates extrapolation of the results to the long-term outcome in men.

Kubin et al. (15) in their experimental studies also performed in mice were the first to underscore the dual role of OSM during heart remodeling following AMI. According to their results, OSM may initially play a protective role for the myocardium, inducing partial de-differentiation of cardiomyocytes, but its chronic influence, associated with the prolonged and extensive cardiomyocytes de-differentiation, may lead to the reduction of the contractile force, development of the ventricular dilation with elevated hemodynamic overload, heart failure and increased mortality (15, 25).

In our study we revealed that patients with acute primary STEMI are characterized by the significant elevation of OSM during the first 24 hours after the event, which is associated with unfavorable outcome in the long-term period. Identified positive associations between the level of OSM and widely studied biomarkers of heart injury and myocardial stress, which are currently used in the protocols for patients’ follow-up after STEMI, is a new finding which allows to regard OSM as a promising laboratory cardio-marker. Even though Bolognese et al. (32) demonstrated increased peak CK-MB in patients with LV remodeling, we did not reveal statistically significant differences in the initial levels of the heart injury biomarkers depending on the presence or absence of LV remodeling. The possible discrepancy of our results with the above mentioned study may be explained by the fact that measurement of the CK-MB activity employed by Bolognese et al. (32) may provide higher results, compared to the measurement of the CK-MB mass, which was performed in our study (33). Hsu et al. (34) have demonstrated that peak CK-MB in combination with dynamic changes of BNP can be used to predict the development of LV remodeling in AMI patients. However, elevated peak CK-MB alone allowed to discriminate LV remodeling development only in non-STEMI patients, but not in STEMI patients, while BNP levels at admission were comparable both in groups with and without LV remodeling. In our study OSM appeared to be more advantageous biomarker for the prognosis of LV remodeling, as its dynamic evaluation was not required as well as its combination with other serum biomarkers was also not necessary.

**Limitations of the study**

The comparatively small number of the recruited patients may be regarded as the major limitation of our study. However, all the patients included in our study, underwent rigorous screening to correspond to the strict inclusion and exclusion criteria, including admission time-frame, existing comorbidities, HF severity, etc. This makes us to believe that the obtained results may also be applicable to a larger cohort of STEMI patients. This does not exclude the necessity of a larger scale studies to be performed to verify the prognostic significance of the OSM early stage elevation in post-infarct heart remodeling.
Conclusions

Thus, patients, who endured primary STEMI, demonstrate elevated concentrations of OSM in peripheral blood during the first 24 h after the event with its subsequent decrease in 6 months. Direct interconnections between OSM and troponin I, Nt-proBNP and CK-MB are detected. The level of OSM during the first 24 h correlates with left ventricular EF, as well as with the value of the LV ESV increase in 6 months after AMI. We have demonstrated that elevated levels of the biochemical marker OSM is associated with the development of the adverse left ventricular remodeling in the long-term post-infarction period and may be used to increase the efficiency of the laboratory diagnostics in patients, who experienced the primary STEMI.

Conflict of interest statement

All the authors declare that they have no conflict of interest in this work.

References

1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39(2): 119–77.

2. Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovasc Disord 2017; 17: 53.

3. Bahit MC, Kochar A, Granger CB. Post-myocardial infarction heart failure. J Am Coll Cardiol HF 2018; 6: 179–86.

4. Mareev VY, Ageev FT, Arutyunov GP, et al. National recommendations of OSSN, RKO and RNMOT on diagnosis and treatment of CHF (fourth revision) // Journal of Heart Failure 2013; 7: 0579–472.

5. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015; 131(4): e29–322.

6. Li J, Dharmarajan K, Bai X, et al. Thirty-day hospital readmission after acute myocardial infarction in China. Circ Cardiovasc Qual Outcomes 2019; 12(5):e005628.

7. Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction. Circ Res 2016; 119: 91–112.

8. Konstantinova EV, Konstantinova NA. Cellular and molecular mechanisms of inflammation in pathogenesis of myocardial infarction (Literature review). Vestnik RGMU 2010; 1: 60–4.

9. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 2018; 18(12): 775–89.

10. Avci E, Karabulut A, Alp AG, Baba B, Bilgi C. Crucial markers showing the risk of coronary artery disease in obesity: ADMA and neopterin. J Med Biochem 2020; 39(4): 452–9.

11. Hohensinner PJ, Kaun C, Rychli K, et al. The inflammatory mediator oncostatin M induces stromal derived factor-1 in human adult cardiac cells. FASEB J 2009; 23(3): 774–82.

12. Zhang X, Li J, Qin J-J, et al. Oncostatin M receptor deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages. J Lipid Res 2017; 58: 895–906.

13. Stawski L, Trojanowska M. Oncostatin M and its role in fibrosis. Connect Tissue Res 2019; 60(1): 40–9.

14. Kubin T, Pöling J, Kostin S, et al. Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling. Cell Stem Cell 2011, 9(5): 420–32.

15. Richards CD, Botelho F. Oncostatin M in the regulation of connective tissue cells and macrophages in pulmonary disease. Biomedicines 2019; 7(4): 95.

16. Hu J, Zhang L, Zhao Z, et al. OSM mitigates post-infarction cardiac remodeling and dysfunction by up-regulating autophagy through Mst1 suppression. Biochim. Biophys. Acta Mol Basis Dis 2017; 1863(8): 1951–61.

17. Kovalyova ON, Kochubei A. Oncostatin M is a proinflammatory cytokines and its role in the cardiovascular disease. Scientific statements BelSU. Series: Medicine 2014; 11(182): 5–8.

18. Hermanns HM. Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev 2015; 26(5): 545–58.

19. West NR, Owens BMJ, Hegazy AN. The oncostatin M–stromal cell axis in health and disease. Scand J Immunol 2018; 88(3): e12694. doi: 10.1111/sji.12694

20. Szibor M, Pöling J, Warnecke H, et al. Remodeling and dedifferentiation of adult cardiomyocytes during disease and regeneration. Cell Mol Life Sci 2014; 71(10): 1907–16.

21. Ikeda S, Sato K, Takeda M, et al. Oncostatin M is a novel biomarker for coronary artery disease - A possibility as a screening tool of silent myocardial ischemia for diabetes mellitus. Int J Cardiol Heart Vasc 2021; 35: 100829.

22. Gruson D, Ferracin B, Ahn SA, Rousseau MF. Elevation of plasma oncostatin M in heart failure. Future Cardiol 2017; 13(3): 219–27.

23. Galli A, Lombardi F. Postinfarct Left Ventricular Remodelling: A prevailing cause of heart failure.
25. Zhang X, Zhu D, Wei L, et al. OSM enhances angiogenesis and improves cardiac function after myocardial infarction. Biomed Res Int 2015; 2015: 317905.

26. Li X, Zhang X, Wei L, et al. Relationship between serum oncostatin M levels and degree of coronary stenosis in patients with coronary artery disease. Clinical Laboratory 2014; 60(1): 115–8.

27. Ashcheulova T, Kochubiei O, Demydenko G, et al. Oncostatin M, interleukin-6, glucometabolic parameters and lipid profile in hypertensive patients with prediabetes and type 2 diabetes mellitus. Rom J Diabetes Nutr Metab Dis 2017; 24(4): 345–54.

28. Xie J, Zhu S, Dai Q, et al. Oncostatin M was associated with thrombosis in patients with atrial fibrillation. Medicine 2017; 96(18): e6806.

29. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 2018; 18(12): 773–89.

30. Nagata T, Kai H, Shibata R, et al. Oncostatin M, an interleukin-6 family cytokine, upregulates matrix metallopro-teinase-9 through the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cultured smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23(4): 588–93.

31. Han H, Dai D, Du R, et al. Oncostatin M promotes infarct repair and improves cardiac function after myocardial infarction. Am J Transl Res 2021; 13(10): 11329–40.

32. Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 2002; 106(18): 2351–7.

33. Marwah SA, Shah H, Chauhan K, et al. Comparison of mass versus activity of creatine kinase MB and its utility in the early diagnosis of re-infarction. Indian J Clin Biochem 2014; 29(2): 161–6.

34. Hsu JT, Chung CM, Chu CM, et al. Predictors of left ventricle remodeling: combined plasma B-type natriuretic peptide decreasing ratio and peak creatine kinase-MB. Int J Med Sci 2017; 14(1): 75–85.